Skip to main content

Mark Cuban Takes On Walgreens, CVS, Amazon in Crowded Drug Space

The Dallas-based online pharmacy on Wednesday debuted its services with a goal to help shield consumers from inflated drug prices.

Mark Cuban is taking on leading online pharmacies Walgreens  (WBA) - , CVS  (CVS) -  and Rite Aid  (RAD) - , as well as newcomer Amazon  (AMZN) - , with the launch of his discount e-commerce pharmacy.

Mark Cuban Cost Plus Drug Co. on Wednesday debuted its services just weeks after establishing its pharmacy benefit manager operation with a goal to help shield consumers from inflated drug prices, .


Global online pharmacy market in 2020 was estimated at over $68 billion, according to .

Amazon, which purchased online pharmacy PillPack in 2018 for $753 million, launched its e-commerce drugstore Amazon Pharmacy in 2020. In May, the company also was considering a move to open pharmacies in its Whole Foods stores as well as brick-and-mortar storefronts, according to a .

About 18 million Americans were recently unable to pay for at least one prescription medication for their household due to ever-rising costs, according to a September 2021 Gallup poll, and one in 10 Americans have skipped doses to save money, the statement said.

Scroll to Continue

bovada Recommends

Promising Significant Prescription Savings

Among the medications that offer significant savings are leukemia treatment Imatinib, which has a $9,657 a month retail price but will only cost $47 through Mark Cuban Cost Plus. Ulcerative colitis treatment Mesalamine, which retails for $940 a month, costs $32.40 through the new e-commerce pharmacy.

Finally, gout treatment Colchicine, which retails for $182 a month, costs $8.70 a month.

In November 2021, Mark Cuban Cost Plus entered the pharmacy benefit manager industry to serve companies providing prescription coverage in their employee benefit plans. The company has pledged to be "radically transparent" in its own negotiations with drug companies, revealing the true costs it pays for drugs and eliminating spread pricing and misaligned rebate incentives. 

"There are numerous bad actors in the pharmaceutical supply chain preventing patients from getting affordable medicines," Oshmyansky said. "The only way to ensure affordable prices get through is to vertically integrate."